[go: up one dir, main page]

ZA200800466B - Novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders - Google Patents

Novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders

Info

Publication number
ZA200800466B
ZA200800466B ZA200800466A ZA200800466A ZA200800466B ZA 200800466 B ZA200800466 B ZA 200800466B ZA 200800466 A ZA200800466 A ZA 200800466A ZA 200800466 A ZA200800466 A ZA 200800466A ZA 200800466 B ZA200800466 B ZA 200800466B
Authority
ZA
South Africa
Prior art keywords
stimulators
activators
prevention
treatment
guanylate cyclase
Prior art date
Application number
ZA200800466A
Other languages
English (en)
Inventor
Krahn Thomas
Stasch Johannes-Peter
Weimann Gerrit
Thielemann Wolfgang
Rinke Matthias
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of ZA200800466B publication Critical patent/ZA200800466B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA200800466A 2005-07-18 2008-01-16 Novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders ZA200800466B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05015522 2005-07-18

Publications (1)

Publication Number Publication Date
ZA200800466B true ZA200800466B (en) 2009-05-27

Family

ID=37075729

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200800466A ZA200800466B (en) 2005-07-18 2008-01-16 Novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders

Country Status (13)

Country Link
US (1) US20100016305A1 (xx)
EP (1) EP1906957A1 (xx)
JP (1) JP2009501739A (xx)
KR (1) KR20080030669A (xx)
CN (1) CN101222923A (xx)
AU (1) AU2006272088A1 (xx)
BR (1) BRPI0614001A2 (xx)
CA (1) CA2615426A1 (xx)
IL (1) IL188657A0 (xx)
MX (1) MX2008000779A (xx)
RU (1) RU2008105481A (xx)
WO (1) WO2007009607A1 (xx)
ZA (1) ZA200800466B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007015034A1 (de) * 2007-03-29 2008-10-02 Bayer Healthcare Ag Lactam-substituierte Dicarbonsäuren und ihre Verwendung
WO2010065275A1 (en) 2008-11-25 2010-06-10 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
WO2011056511A2 (en) 2009-10-26 2011-05-12 Auspex Pharmaceuticals, Inc. 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase
DE102009046115A1 (de) * 2009-10-28 2011-09-08 Bayer Schering Pharma Aktiengesellschaft Substituierte 3-Phenylpropansäuren und ihre Verwendung
WO2011119518A1 (en) 2010-03-25 2011-09-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
NZ603799A (en) * 2010-05-26 2014-10-31 Bayer Ip Gmbh The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of systemic sclerosis (ssc).
BR112012030177B1 (pt) 2010-05-27 2019-08-27 Merck Sharp & Dohme composto ativador da guanilato ciclase solúvel, e, composição farmacêutica
EP2687210A1 (de) * 2010-06-25 2014-01-22 Bayer Intellectual Property GmbH Verwendung von Stimulatoren und Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Sichelzellanämie und Konservierung von Blutersatzstoffen
EP2683710B1 (en) 2011-03-10 2017-07-19 Boehringer Ingelheim International GmbH Soluble guanylate cyclase activators
JP5826393B2 (ja) 2011-08-12 2015-12-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性グアニル酸シクラーゼ活性化因子
SI2892891T1 (sl) 2012-09-07 2019-11-29 Boehringer Ingelheim Int Alkoksi pirazoli kot topni aktivatorji gvanilat-ciklaze
EP4223339B1 (en) * 2013-03-14 2025-01-29 Fisher & Paykel Healthcare Limited Catheter mount with suction port
WO2015021358A2 (en) * 2013-08-09 2015-02-12 Dominique Charmot Compounds and methods for inhibiting phosphate transport
EP3119316B1 (en) * 2014-03-17 2020-05-27 Intuitive Surgical Operations, Inc. Sterile drape with sterile adapter comprising mounting datum for surgical instrument
SG10201806565SA (en) 2014-07-22 2018-08-30 Boehringer Ingelheim Int Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
CN104434845B (zh) * 2014-11-12 2017-12-05 广东东阳光药业有限公司 一种包含利奥西呱的固体药物制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69928260T2 (de) * 1998-07-08 2006-07-20 Sanofi-Aventis Deutschland Gmbh Schwefel-substituierte sulfonylaminocarbonsäure n-arylamide, ihre herstellung, ihre anwendung und diese enthaltende pharmazeutische zusammensetzungen
DE19834044A1 (de) * 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943635A1 (de) * 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) * 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10351903A1 (de) * 2003-11-06 2005-06-09 Bayer Healthcare Ag Neue Kombination
DE102004012365A1 (de) * 2004-03-13 2005-09-29 Bayer Healthcare Ag Substituierte Dihydropyridine

Also Published As

Publication number Publication date
KR20080030669A (ko) 2008-04-04
US20100016305A1 (en) 2010-01-21
JP2009501739A (ja) 2009-01-22
CA2615426A1 (en) 2007-01-25
CN101222923A (zh) 2008-07-16
WO2007009607A1 (en) 2007-01-25
IL188657A0 (en) 2008-12-29
BRPI0614001A2 (pt) 2011-03-01
EP1906957A1 (en) 2008-04-09
MX2008000779A (es) 2008-02-21
RU2008105481A (ru) 2009-08-27
AU2006272088A1 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
ZA200800466B (en) Novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders
IL177772A0 (en) Methods and compositions for the treatment of gastrointestinal disorders
EP1853295A4 (en) METHOD AND COMPOSITIONS FOR TREATING GASTROINTESTINAL DISEASES
ZA200607433B (en) Methods and compositions for the treatment of gastroin-testinal disorders
EP1940441A4 (en) COMPOSITIONS AND METHODS FOR TREATING GASTROINTESTINAL DISORDERS
PT1644021E (pt) Métodos e composições para o tratamento de distúrbios gastrointestinais
GB2421260B (en) Well treating compositions for slow release of treatment agents and methods of using the same
ZA200700223B (en) Quinazolin-4-yl-piperidine and cinnolin-4-yl-peperidine derivatives as PDE10 inhibitors for the treatment of CNS disorders
IL179508A0 (en) 2-substituted-4- heteroaryl-pyrimidines useful for the treatment of proliferative disorders
IL183537A0 (en) Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
HUE059861T2 (hu) N-Szubsztituált 2,5-dioxo-azolin vegyületek a rák kezelésében való felhasználásra
IL191832A0 (en) Pyridiazinone derivatives for the treatment of tumours
IL191137A0 (en) Polycation-polyanion complexes, compositions and methods of use thereof
ZA200701193B (en) The use of N-aryl diazaspiracyclic compounds in the treatment of addiction
IL188390A0 (en) Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
IL187565A0 (en) Compositions and methods for the treatment or prevention of chemoresistant neoplasia
IL189009A0 (en) Methods and compositions for the treatment of neuropathies and related disorders
IL191537A0 (en) Methods and compositions for the treatment of gastrointestinal disorders
IL183656A0 (en) Indenyl derivatives and use thereof for the treatment of neurological disorders
IL178816A0 (en) The treatment of childhood asthma
ZA200702421B (en) Iron complex for use in the treatment and/or prevention of nutritional disorders
GB0722578D0 (en) Methods and compositions for delaying the release of treatment chemicals
IL185770A0 (en) Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia
IL190619A0 (en) Use of soluble guanylate cyclase activators for treating acute and chronic lung diseases
PL378587A1 (pl) Sposób wytwarzania (S)-(-)-2-amino-6-n-propyloamino-4,5,6,7-tetrahydrobenzotiazolu i/lub jego soli